ReShape Lifesciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ReShape Lifesciences generated cash of -$16,960,000, which is more than the previous year. Cash used in financing activities reached the amount of $17,574,000 last year. Net change in cash is therefore $604,000.
Cash Flow
| 2014 | -19.38M | -88.68K | 7.79M |
|---|---|---|---|
| 2015 | -22.60M | -38.91K | 18.95M |
| 2016 | -20.65M | -14K | 16.05M |
| 2017 | -24.58M | -6.36M | 37.80M |
| 2018 | -27.49M | -10.32M | 33.20M |
| 2019 | -14.2M | -2.01M | 13.65M |
| 2020 | -8.55M | -2.39M | 11.07M |
| 2021 | -15.37M | 1.85M | 33.29M |
| 2022 | -21.90M | -92K | 3.13M |
| 2023 | -16.96M | -10K | 17.57M |
RSLS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.95M | 22.81M | 3.00M | 2.98M | 5.54M | 10.16M | 3.31M | 7.92M | 11.61M | 23.29M |
Operating activities | ||||||||||
Net income | -11.38M | -46.21M | -61.93M | -21.63M | -74.20M | -35.26M | -33.81M | -23.36M | -25.49M | -26.12M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 154K | 2.15M | 1.97M | 1.66M | 1.70M | 440.55K | 925.46K | 139.57K | 188.60K | 188.90K |
Stock-based compensation expense | 766K | 2.08M | 12.22M | 1.32M | 2.31M | 0 | 4.43M | 2.33M | 6.93M | 6.31M |
| Deferred income tax benefit | 766K | 2.08M | 12.22M | 1.32M | 2.31M | 0 | 4.43M | 2.33M | 6.93M | 6.31M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 125K | 678K | -284K | 285K | 585K | -507.89K | 28.10K | -105.62K | -55.11K | 14.93K |
Inventories | -465K | -1.18M | -369K | -1.17M | -332K | 1.97M | 68.44K | -103.25K | -705.80K | 147.42K |
Accounts payable | -3.45M | 448K | -1.48M | -33K | -543K | 317.08K | -223.43K | 1.13M | -222.63K | 267.35K |
Cash generated by operating activities | -16.96M | -21.90M | -15.37M | -8.55M | -14.2M | -27.49M | -24.58M | -20.65M | -22.60M | -19.38M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -39K | 0 | 0 | 0 | -9.10M | -94.61M | -18.89M | -18.59M | 0 |
Investments In Property Plant And Equipment | -43K | -131K | -352K | -390K | -14K | -49.57K | -137.12K | -14K | -38.91K | -88.68K |
Acquisitions Net | 0 | 39K | 2.20M | -2M | -2M | -10.27M | -6.23M | 0 | 6K | 0 |
Cash generated by investing activities | -10K | -92K | 1.85M | -2.39M | -2.01M | -10.32M | -6.36M | -14K | -38.91K | -88.68K |
Financing activities | ||||||||||
Common Stock Issued | 17.57M | 639K | 2.81M | 679K | 478K | 0 | 6.46M | 14.51M | 22.65M | 9.83M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -10.5M | -10.39M | 0 | 0 | 0 | -446.86K | 5M | -4M |
Cash used in financing activities | 17.57M | 3.13M | 33.29M | 11.07M | 13.65M | 33.20M | 37.80M | 16.05M | 18.95M | 7.79M |
Net Change In Cash | 604K | -18.86M | 19.80M | 22K | -2.56M | -4.61M | 6.85M | -4.61M | -3.69M | -11.67M |
Cash at end of period | 4.55M | 3.95M | 22.81M | 3.00M | 2.98M | 5.54M | 10.16M | 3.31M | 7.92M | 11.61M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |